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Abstract
Background: We investigated the association between anemia and functional mitral regur-
gitation (MR) in non-ischemic dilated cardiomyopathy (DCM) patients with sinus rhythm
and normal renal function.
Methods: Sixty non-ischemic DCM patients with sinus rhythm and left ventricular ejection
fraction < 40% were recruited. Functional MR was quantified with the proximal isovelocity
surface area method. MR was graded according to the mitral regurgitant volume (Reg Vol) or
effective regurgitant orifice (ERO) area. The clinical, biochemical and echocardiographic
correlates of functional MR severity were investigated in patients with DCM.
Results: Hemoglobin degrees were significantly different between various MR levels (mild
MR 13.9 ± 1.7 mg/dL, moderate MR 12.3 ± 1.5 mg/dL, moderate to severe MR 10.8 ± 0.9 mg/dL).
Receiver operating characteristic (ROC) analysis was performed to assess the utility of hemo-
globin levels to predict moderate or severe functional MR. A hemoglobin level less than
12.5 mg/dL predicted moderate or high MR with 80% sensitivity and 58% specificity (AUC:
0.789, 95% CI: 0.676–0.901, p < 0.0001). Logistic regression analysis was performed to
determine the independent predictors of moderate or severe levels of MR. The left atrium
diameter (OR: 19.3, 95% CI: 1.4–27.1, p = 0.028) and presence of anemia (OR: 11.9,
95% CI: 1.22–42.5, p = 0.0045) were independent predictors of moderate or severe functional MR.
Conclusions: The presence of anemia and enlarged left atrium are independent predictors of
moderate or severe functional MR in non-ischemic DCM patients with normal renal function.
Hemoglobin levels less than 12.5 mg/dL should alert the physician for the presence of moderate
or severe MR in patients with DCM. (Cardiol J 2010; 17, 3: 274–280)
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Introduction
Recent studies have revealed that patients with
chronic heart failure (CHF) are frequently anemic,
and that anemia is associated with increased mor-
tality and morbidity in these patients [1–4]. Eze-
kowitz et al. [1] demonstrated that anemia was
present in 17% of more than 12,000 heart failure
patients and associated with a hazard ratio of 1.34
for mortality. Functional mitral regurgitation (MR)
is another adverse prognostic factor in patients with
dilated cardiomyopathy (DCM) [5, 6]. Blondheim et
al. [5] reported that the presence of MR is a sensi-
tive marker of decreased survival. They reported
a significant difference in survival (22% vs 60% at
32 months, p < 0.005) in DCM patients with and with-
out MR. However, the association between anemia
and functional MR is unclear in DCM. In our study,
we investigated the relation between hemoglobin le-
vels and functional MR in non-ischemic DCM patients
with sinus rhythm and normal renal functions.
Methods
The study population was selected from patients
evaluated in Kartal Kosuyolu Heart Education and
Research Hospital cardiology outpatient clinic be-
tween January 2007 and March 2009. All patients who
met the inclusion criteria (presence of heart failure
symptoms, left ventricular ejection fraction < 40%,
sinus rhythm, a coronary angiogram establishing the
non-ischemic origin of heart failure that was per-
formed within the last six months) were asked to par-
ticipate in the study and those who accepted were
enrolled consecutively in this cross-sectional study.
Following the recruitment period, the study popula-
tion included 60 non-ischemic DCM patients.
The local ethics committee approved this
cross-sectional study.
Patients with organic heart valve diseases that
may cause mitral regurgitation (rheumatic or de-
generative heart valve disease, mitral annular cal-
cification, mitral valve prolapsus, chordae tendinea
rupture), history of acute coronary syndrome,
ischemic electrocardiographic (ECG) findings, sig-
nificant coronary artery disease in coronary angio-
graphy (> 50% luminal stenosis), permanent pace-
makers, and chronic kidney disease (> stage 3 kid-
ney disease) were excluded from the study. All patients
were evaluated carefully for their functional capaci-
ties. 12-lead ECGs were obtained (0.5 to 150 Hz,
25 mm/s, 10 mm/mV). Blood samples for N-termi-
nal pro-brain natriuretic peptide (NT-proBNP)
levels, hemoglobin, hematocrit, blood erythrocyte
count, and creatinine levels were obtained following
a resting period after the echocardiographic exami-
nations. Patients were categorized into two groups
according to their QRS interval time (< 120 ms,
≥ 120 ms). The World Health Organization defini-
tion of anemia (hemoglobin concentration 13.0 g/dL
in men and 12.0 g/dL in women) was used in the
classification of patients with or without anemia [7].
Echocardiographic examinations
Standard echocardiographic evaluations with
Doppler study were performed (System 5,
Vingmed-General Electric, Horten, Norway). Left
ventricle (LV) dimensions and ejection fractions
were measured by modified biplane Simpson’s
method according to the guidelines of the Ameri-
can Society of Echocardiography [8]. The quantifi-
cation of functional mitral regurgitation was per-
formed by using the proximal isovelocity surface
area method as previously described [9]. The effec-
tive regurgitation orifice (ERO) area [cm2] and the
regurgitatnt volume (Reg Vol) [mL] were used as
variables expressing the severity of MR. The maxi-
mal rate of left ventricular systolic pressure in-
crease (LV dP/dt) was used as an index of LV systo-
lic performance and estimated from the steepest in-
creasing segment of the continuous wave Doppler
MR velocity spectrum [10]. Pulmonary artery
systolic pressure was estimated from the tricuspid
regurgitation jet by continuous wave Doppler. Pa-
tients were subdivided into four groups based on their
Reg Vol or ERO (mild MR: Reg Vol < 20 mL/beat
or ERO < 0.20 cm2, moderate MR: Reg Vol = 20–
–39 mL/beat or ERO = 0.20–0.29 cm2, moderate to
severe MR: Reg Vol = 40–59 mL/beat or ERO =
= 0.30–0.39 cm2, severe MR: Reg Vol > 60 mL/beat
or ERO > 0.40 cm2) and the clinical, biochemical,
and echocardiographic correlates of functional MR
degree in patients with DCM were investigated.
Tissue Doppler imaging (TDI) was performed
in the apical views (four chamber and long axis) for
the long axis motion of the LV and tricuspid annu-
lus with a 2.5 MHz phase array transducer as pre-
viously described [11, 12]. For detailed assessment
of regional myocardial function, the sampling window
was placed at the myocardial segment of interest.
In the apical four-chamber view, left ventricular
septal and lateral wall and lateral tricuspid annu-
lus were assessed. Myocardial sustained systolic
(s), early diastolic (e), and late diastolic (a) veloc-
ities from the basal septal and tricuspid annulus
were calculated.
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NT-proBNP levels
Plasma NT-proBNP levels were obtained after
a 20 minute rest following the echocardiographic
evaluation. All of the blood samples were drawn
from the antecubital vein. Samples were kept in
vacutainers with EDTA, and centrifuged for 5 min
at 1500 rpm. Separated plasma samples were kept
at –80oC until the analysis date. Commercial
NT-proBNP assays (Elecsys, Roche Diagnostics
Corporation, Indianapolis, Indiana, USA) were used
for measurements.
Statistical analysis
Statistical analysis was performed using a sta-
tistical software program (SPSS for Windows, ver-
sion 13.0; SPSS Inc, Chicago, Illinois, USA). Data
are presented as mean ± standard deviation, con-
trolled for normal distribution by Kolmogorov-Smir-
nov test and compared using unpaired student t-test
when normally distributed. Nonparametric tests
were also applied in non-normal distributions
(Mann-Whitney U test). Categorical differences be-
tween two groups were compared by the Pearson
c2 test. The difference in hemoglobin levels be-
tween various degrees of MR was evaluated by
analysis of variance (ANOVA) test. Hemoglobin
levels were evaluated by receiver operating char-
acteristics (ROC) analysis in predicting functional
MR. In order to determine the optimal hemoglobin
value in predicting moderate or higher levels of MR,
the closest value to the best specificity and sensi-
tivity point on the ROC curve was identified. Lo-
gistic regression analysis was used to identify the
independent predictors of moderate or higher le-
vels of MR out of the clinical, ECG, and echocardi-
ographic parameters. A probability value of p < 0.05
was considered as significant.
Results
The study population included 22 women (37%)
and 38 men (63%). Mean age was 43 ± 15. Twen-
ty-three patients (38%) were anemic. Anemic pa-
tients had larger left atrial diameters (p = 0.012),
greater mitral Reg Vol (p < 0.0001) and ERO areas
(p < 0.0001), shorter E wave deceleration (p =
= 0.026) and isovolumic relaxation times (p = 0.007),
and lower TDI derived tricuspid annulus peak systo-
lic velocities (RVs; p = 0.002) compared to non-
-anemic patients. Eight of the 23 patients were in
NYHA functional class III–IV in the anemic group;
five out of 37 patients in the non-anemic group were
in NYHA functional class III–IV (Pearson c2: 3.78,
p = 0.048). The remaining clinical, electrocardio-
graphic, biochemical and echocardiographic para-
meters were similar between the two groups. The
characteristics of patients with and without anemia
are reported in Table 1.
The difference in hemoglobin levels in pa-
tients with various degrees of MR was evaluated
by ANOVA. Thirty-six patients (60%) had mild,
20 patients (33.3%) had moderate, and four (6.6%)
patients had moderate to severe MR. There was no
patient with severe MR. The hemoglobin levels
were significantly different between various MR
levels (mild MR; 13.9 ± 1.7 mg/dL, moderate MR;
12.3 ± 1.5 mg/dL, moderate to severe MR; 10.8 ±
± 0.9 mg/dL; p = 0.001 for mild and moderate MR,
p = 0.001 for mild and moderate to severe MR,
p = 0.062 for moderate and moderate to severe
MR). Significant correlations between Reg Vol,
echocardiographic and biochemical parameters are
reported in Table 2.
The study group was categorized into two sub-
groups according to the MR severity which was de-
termined by the Reg Vol 20 mL/beat or ERO area
0.20 cm2. Patients with mild MR constituted Group I
(n = 36) and those with higher degrees of MR Group
II (n = 24). The patients in Group II had larger left
atrial (p < 0.0001), left ventricular end-systolic
(p < 0.0001), end-diastolic dimensions (p = 0.001),
and lower left ventricular ejection fraction (p =
= 0.027), septum TDI peak systolic velocity (Sep
TDIs) (p = 0.008), and RVs (p = 0.023) than the
patients in Group I. Mitral E wave velocity (p < 0.0001)
and E/A ratio (p = 0.002) were elevated, E wave dece-
leration (p < 0.0001) and isovolumic relaxation times
(p < 0.0001) were shorter, hemoglobin (p < 0.0001)
and hematocrit (p = 0.002) levels were lower in
Group II patients.  Four of 36 patients (11%) in
Group I and nine of 24 patients (37.5%) in Group II
were in NYHA functional class III–IV (Pearson c2:
5.9, p = 0.015). Eight of 36 patients (22%) in Group
I and 15 of 24 patients (62.5%) in Group II were
anemic (Pearson c2: 9.88, p = 0.002). Characteris-
tics of the patients in Group I and Group II are re-
ported in Table 3.
ROC analysis was performed to assess the utility
of hemoglobin to predict moderate or severe levels
of functional MR. A hemoglobin level less than
12.5 mg/dL predicted moderate or higher MR with
80% sensitivity and 58% specificity (AUC: 0.789,
95% CI: 0.67–0.90, p < 0.0001) (Fig. 1). Logistic re-
gression analysis was also performed to evaluate the
independent predictors of moderate or severe  le-
vels of MR. NYHA functional class (class I–II vs class
III–IV), plasma NT-proBNP levels, left ventricular
ejection fraction, left atrium diameter, left ventricu-
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lar end-systolic and end-diastolic dimensions, E/A ra-
tio, Sep TDIs, RVs and anemia (presence of anemia
or not) were the covariates and included in the mo-
del. Logistic regression analysis revealed left atrial
diameter (OR: 19.3, 95% CI: 1.4–27.1, p = 0.028),
and the presence of anemia (OR: 11.9, 95% CI: 1.22–
–42.5, p = 0.0045) were the independent predictors
of moderate or higher levels of functional MR.
Discussion
Our study indicates that non-ischemic DCM
patients with anemia have higher degrees of func-
tional MR and enlarged left atria. In addition, these
patients had impaired tissue Doppler derived right
ventricular systolic function. Patients with higher
NYHA functional class were also more prevalent in
this group. Hemoglobin levels less than 12.5 mg/dL
indentified the non-ischemic DCM patients with
moderate or higher degrees of functional MR.
The estimated prevalence of anemia in patients
with CHF ranges from 4% to 61% (median 18%).
Table 1. Characteristics of non-ischemic dilated cardiomyopathy patients with and without anemia.
Anemia (+); n = 23 Anemia (–); n = 37 P
Gender (female/male) 8 (35%)/15 (65%) 14 (38%)/23 (62%) 0.811
Age (years) 40±16 44±14 0.394
NYHA class I–II/III–IV 15 (65%)/8 (35%) 32 (86%)/5 (14%) 0.048
QRS duration (< 120/≥ 120) 17 (74%)/6 (26%) 25 (68%)/12 (32%) 0.555
Log NT-proBNP 3.14±0.5 2.92±0.6 0.225
Hemoglobin 11.4±1.1 14.3±1.3 < 0.0001
Hematocrit 34.4±3.2 41.8±4.1 < 0.0001
LA [cm] 4.9±0.9 4.3±0.7 0.012
LVEDD [cm] 7.1±0.9 6.7±0.8 0.094
LVESD [cm] 6.2±0.8 5.8±0.8 0.067
LVEF (%) 28.1±9 30.4±6 0.297
dP/dt [mm Hg/ms] 524±149 572±148 0.252
Mitral Reg Vol [mL] 29±13 16±8 < 0.0001
ERO [cm2] 0.22±0.12 0.12±0.07 < 0.0001
Mitral E vel. [m/s] 0.97±0.31 0.82±0.27 0.089
Mitral A vel. [m/s] 0.53±0.20 0.60±0.24 0.285
E/A 2.14±1.1 1.67±0.9 0.130
EDT [ms] 128±56 170±71 0.026
IVRT [ms] 87±32 114±26 0.007
RV TDI s [cm/s] 7.4±2.7 9.5±2.1 0.002
Sep TDI s [cm/s] 3.1±1.4 3.5±1.1 0.061
Sep TDI e [cm/s] 3.5±1.9 3.7±1.9 0.655
Sep TDI a [cm/s] 3.8±2.0 4.3±1.7 0.316
E/e’ 38.8±29 28.6±17 0.103
dP/dT — delta pressure/delta time; EDT — E wave deceleration time; ERO — effective regurgitant orifice area; IVRT — isovolumic relaxation time;
LA — left atrium diameter; LVEDD — left ventricular end-diastolic diameter; LVEF — left ventricular ejection fraction; LVESD — left ventricular end-
-systolic diameter; NYHA — New York Heart Association; Reg Vol — regurgitant volume; RV TDI s — tricuspid annulus TDI peak systolic velocity;
Sep TDI a — basal septum TDI late diastolic velocity; Sep TDI e — basal septum TDI early diastolic velocity; Sep TDI s — basal septum TDI peak systolic
velocity
Table 2. Correlations between mitral regurgitant
volume and echocardiographic and biochemical
parameters.
R P
ERO area [mm2] 0.850 < 0.0001
Log NT-proBNP 0.407 0.003
NYHA class I–II/III–IV 0.351 0.006
LA [cm] 0.554 < 0.0001
LVEDD [cm] 0.412 0.001
LVESD [cm] 0.467 < 0.0001
LVEF (%) –0.306 0.017
E/A 0.402 0.007
PAP [mm Hg] 0.398 0.02
RV TDI s [cm/s] –0.405 0.001
Sep TDI s [cm/s] –0.350 0.007
Hemoglobin [mg/dL] –0.551 < 0.0001
Hematocrit (%) –0.457 < 0.0001
ERO — effective regurgitant orifice area; NYHA — New York Heart
Association; LA — left atrium diameter; LVEDD — left ventricular
end-diastolic diameter; LVESD — left ventricular end systolic diame-
ter; LVEF — left ventricular ejection fraction; PAP — pulmonary arte-
ry systolic pressure,;RV TDI s — tricuspid annulus TDI peak systolic
velocity; Sep TDI s — basal septum TDI peak systolic velocity
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The prevalence of anemia is increased in CHF pop-
ulations with comorbid kidney disease, advanced
age, and more severe heart failure symptoms [13].
Anemia was found to be an independent predictor
of high mortality and poor clinical outcomes in pa-
tients with advanced heart failure [2, 4, 14]. It is
unclear whether anemia worsens heart failure or it
is just a marker of more severe underlying myocar-
dial disease. Anemia can also be a marker of more
severe underlying myocardial disease.
On the other hand, the presence of functional
MR is also considered to be a risk factor for poor
clinical outcome in DCM [5, 15]. Functional MR is
associated with poor NYHA functional class, lower
left ventricular ejection fraction, higher left ven-
tricular end-diastolic and right sided pressures in
patients with DCM [15]. Functional MR results in
more left ventricular dilatation, and aggravates the
hemodynamic decompensation. In patients with
moderate to severe MR, anemia may be an addition-
al contributing factor to hemodynamic and function-
al decompensation and poor clinical outcome in non-
-ischemic DCM patients. In addition, right ventricu-
lar systolic performance is an important predictor
of morbidity and mortality in ischemic and non-
ischemic DCM [16–18]. Patients with left ventricu-
lar end-diastolic diameter > 70 mm and RVs <
10.8 cm/s are the highest risk heart failure group
independent from the etiology. This condition is
even more peculiar in patients with DCM [16]. We
found that tissue Doppler derived right ventricular
systolic function was significantly impaired in ane-
mic DCM patients in our study.
Although there are controversies about the
effect of anemia on poor left ventricular function and
severely limited exercise capacity [19–21], medi-
cal management of anemia has been demonstrated
to improve functional capacity and quality of life in
Table 3. Characteristics of non-ischemic dilated cardiomyopathy patients with mild and moderate or
higher levels of functional mitral regurgitation (MR).
Group I; n = 36 Group II; n = 24 P
MR volume < 20 mL MR volume ≥ 20 mL
Gender (female/male) 14 (39%)/22 (61%) 8 (33%)/16 (67%) 0.662
Age (years) 44±15 40±16 0.252
NYHA class I–II/III–IV 32 (89%)/4 (11%) 15 (62%)/9 (38%) 0.015
QRS duration (< 120/≥ 120) 26 (72%)/10 (28%) 15 (62%)/9 (38%) 0.334
Log NT-proBNP 2.88±0.6 3.22±0.5 0.052
Hemoglobin 13.9±1.7 12.1±1.5 < 0.0001
Hematocrit 40.6±5.1 36.4±4.3 0.002
LA [cm] 4.2±0.6 5.0±0.8 < 0.0001
LVEDD [cm] 6.6±0.8 7.3±0.7 0.001
LVESD [cm] 5.6±0.8 6.4±0.6 < 0.0001
LVEF (%) 31.1±7 27.1±7 0.027
dP/dt [mm Hg/ms] 592±149 496±131 0.014
Mitral Reg Vol [mL] 12.5±4.1 33.6±9.3 < 0.0001
ERO [cm2] 0.09±0.03 0.25±0.11 < 0.0001
Mitral E vel. [m/s] 0.75±0.25 1.07±0.24 < 0.0001
Mitral A vel. [m/s] 0.62±0.24 0.50±0.19 0.052
E/A 1.52±1 2.40±0.8 0.002
EDT [ms] 180±72 114±36 < 0.0001
IVRT [ms] 116±26 85±29 < 0.0001
RV TDI s [cm/s] 9.3±2.2 7.8±2.8 0.023
Sep TDI s [cm/s] 3.7±1.2 2.8±1.0 0.008
Sep TDI e [cm/s] 3.6±2.0 3.7±1.8 0.891
Sep TDI a [cm/s] 4.4±1.8 3.6±1.8 0.081
E/e’ 30±26 35±14 0.478
dP/dT — delta pressure/delta time; EDT — E wave deceleration time; ERO — effective regurgitant orifice area; IVRT — isovolumic relaxation time;
LA — left atrium diameter; LVEDD — left ventricular end-diastolic diameter; LVEF — left ventricular ejection fraction; LVESD — left ventricular end-
-systolic diameter; NYHA — New York Heart Association; Reg Vol — regurgitant volume; RV TDI s — tricuspid annulus TDI peak systolic velocity;
Sep TDI a — basal septum TDI late diastolic velocity; Sep TDI e — basal septum TDI early diastolic velocity; Sep TDI s — basal septum TDI peak systolic
velocity
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patients with heart failure [22]. Prediction of mod-
erate or severe functional MR with high sensitivi-
ty and specificity by considering anemia in advance
may be useful in the routine practice. We suggest
that the presence of anemia should alert the physi-
cian to the presence of moderate or higher levels
of MR in DCM patients. Enlarged left atrial dimen-
sions, increased mitral Reg Vol, shorter E wave de-
celeration and isovolumic relaxation times and low-
er RVs in anemic patients suggest that anemia is
a marker of more severe underlying myocardial dis-
ease in non-ischemic DCM patients.
Chronic renal disease is common in patients
with heart failure and their prognosis is usually poor
[23]. Among heart failure patients, anemia is more
common in patients with chronic kidney disease and
has been found to independently confer a two-fold
higher risk of death [24]. In our study, patients with
chronic renal failure were excluded in order to eval-
uate the association between anemia per se and
echocardiographic parameters. In our study, ane-
mia was associated with increased mitral Reg Vol
and impaired right ventricular functions in DCM pa-
tients, despite normal kidney function.
The small study population may be a major limi-
tation. Therefore, our findings need confirmation by
larger studies to increase the significance and cli-
nical accuracy of our results. Whether treatment
of anemia may influence the functional status, mor-
bidity, mortality, and functional MR of non-ischemic
DCM needs further prospective studies.
Conclusions
The presence of anemia independently predicts
moderate or severe levels of functional MR in non-
-ischemic DCM patients with normal kidney func-
tions. Hemoglobin levels less than 12.5 mg/dL
should alert the physician for a moderate or severe
MR in patients with non-ischemic DCM.
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